Results 271 to 280 of about 5,627,179 (327)
Some of the next articles are maybe not open access.

Pulmonary function in thalassemia major

The Journal of Pediatrics, 1987
Pulmonary function tests were evaluated in 28 Chinese patients with beta-thalassemia major receiving regular transfusions and desferoxamine, and in 34 height-matched normal Chinese children. Comparison of lung function using analysis of covariance with reference to standing height showed that patients with thalassemia had a proportional decrease in ...
Fung, K.P.   +3 more
openaire   +2 more sources

Psychosocial implications of Thalassemia Major

Pediatrics International, 2005
Abstract  Background : Many causes including the chronicity of disease, burden of treatment modalities, morbidities, and the expectation of early death resulting from the disease complications, may lead to psychosocial burden in Thalassemia Major (TM) patients.
Aydinok Y.   +4 more
openaire   +3 more sources

Echocardiographic findings in thalassemia major

Acta Paediatrica, 1994
[No abstract available]
Kilinc Y.   +4 more
openaire   +3 more sources

Thalassemia-free and graft-versus-host-free survival: outcomes of hematopoietic stem cell transplantation for thalassemia major, Turkish experience

Bone Marrow Transplantation, 2022
M. A. Yeşilipek   +57 more
semanticscholar   +1 more source

National networking in rare diseases and reduction of cardiac burden in thalassemia major.

European Heart Journal, 2021
A. Pepe   +18 more
semanticscholar   +1 more source

Iron Chelation in Thalassemia Major

Clinical Therapeutics, 2015
Iron chelation has improved survival and quality of life of patients with thalassemia major. there are currently 3 commercially available iron-chelating drugs with different pharmacokinetic and pharmacodynamic activity. The choice of adequate chelation treatment should be tailored to patient needs and based on up-to-date scientific evidence.A review of
BORGNA, Caterina, Marsella, M.
openaire   +2 more sources

Hepcidin and β-thalassemia major

Blood, 2013
In this issue of Blood, Pasricha et al evaluated serum hepcidin and its putative pathological suppressor growth differentiation factor-15 (GDF-15) in patients with β-thalassemia major before and after transfusion, in the context of erythropoietic activity and iron loading.
openaire   +2 more sources

Endocrine Function in Thalassemia Major

The Journal of Clinical Endocrinology & Metabolism, 1968
Abstract Seven patients with thalassemia major, ranging in age from 6½ to 23 yr, were studied. Growth retardation was present in all except the youngest patient. Thyroid and adrenal function was normal. Three patients, however, showed an unexplained increase in the serum protein bound iodine level.
B, Kuo, E, Zaino, M S, Roginsky
openaire   +2 more sources

Renal Enlargement in Thalassemia Major

Radiology, 1971
Twenty-four patients with thalassemia major and no urinary tract complaints underwent excretory urography. The kidneys were large bilaterally in 17 patients; 2 other patients had enlargement of the left kidney. The autopsies of 13 patients were reviewed; the kidneys were large in all 13.
H, Grossman   +3 more
openaire   +2 more sources

Auditory Involvement in Thalassemia Major

Acta Haematologica, 1979
The auditory function of 75 children affected by homozygous beta0-thalassemia, managed with a low transfusion scheme and treated irregularly with low doses of desferrioxamine, and of 75 controls were examined. In 12 patients a mild bilateral conductive hearing impairment due to bony hypertrophy and/or adenoid hypertrophy was found.
S, De Virgiliis   +7 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy